Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Yes, bisphosphonates can cause an unusual type of thigh bone break called an atypical femoral fracture, though this risk is very rare and far outweighed by the medication's proven benefit in preventing common osteoporotic fractures. These breaks occur in the outer thigh bone below the hip and are linked to long-term use, typically beyond three to five years, with risk rising the longer treatment continues. Warning signs often appear weeks or months in advance as a dull, aching pain in the groin, hip, or thigh that worsens with activity, and reporting this pain early allows for imaging before a complete break happens. Doctors may recommend a "drug holiday" after several years of treatment for people at lower risk, while those at high fracture risk often continue therapy because stopping raises the chance of hip and spine fractures. Several important factors affect your individual risk, including treatment duration, bone health, and other medications, so see below to understand more.
Last reviewed for medical accuracy: 08/18/2026
If you are experiencing thigh, hip, or groin pain and are unsure what it means, a free, instant symptom check can help you organize your symptoms and understand which next steps make sense. It takes only a few minutes, requires no sign-up, and gives you clearer language to bring to your doctor so nothing important gets overlooked. Early reporting of unexplained thigh pain is one of the few things known to prevent a partial stress fracture from becoming a complete break, which makes acting now genuinely worthwhile.Yes, bisphosphonates can cause an unusual type of thigh bone break called an atypical femoral fracture, though this risk is very rare and far outweighed by the medication's proven benefit in preventing common osteoporotic fractures. These breaks occur in the outer thigh bone below the hip and are linked to long-term use, typically beyond three to five years, with risk rising the longer treatment continues. Warning signs often appear weeks or months in advance as a dull, aching pain in the groin, hip, or thigh that worsens with activity, and reporting this pain early allows for imaging before a complete break happens. Doctors may recommend a "drug holiday" after several years of treatment for people at lower risk, while those at high fracture risk often continue therapy because stopping raises the chance of hip and spine fractures. Several important factors affect your individual risk, including treatment duration, bone health, and other medications, so see below to understand more.
Last reviewed for medical accuracy: 08/18/2026
If you are experiencing thigh, hip, or groin pain and are unsure what it means, a free, instant symptom check can help you organize your symptoms and understand which next steps make sense. It takes only a few minutes, requires no sign-up, and gives you clearer language to bring to your doctor so nothing important gets overlooked. Early reporting of unexplained thigh pain is one of the few things known to prevent a partial stress fracture from becoming a complete break, which makes acting now gen
Bisphosphonates are a common treatment for osteoporosis and other bone-weakening conditions. Over the last two decades, rare cases of atypical femoral (thigh bone) fractures have been reported in long-term users. This article reviews what is known from credible research, helping you weigh benefits and risks while staying informed and proactive about your bone health.
Bisphosphonates include medications such as alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva) and zoledronic acid (Reclast). They:
Main benefits
• Proven to cut hip and spine fractures by 40–50% in postmenopausal osteoporosis.
• Often well-tolerated; serious side effects are uncommon.
Bone remodeling balance
• In healthy bone, osteoclasts remove old bone and osteoblasts form new bone.
• Bisphosphonates “shift” this balance toward bone formation by suppressing osteoclasts.
Mineralization improvement
• By slowing bone turnover, bisphosphonates allow more complete mineralization, which strengthens bone structure.
Long half-life
• These drugs bind tightly to bone and can remain active for years after stopping therapy.
While bisphosphonates reduce common fracture types, “atypical femoral fractures” (AFFs) have emerged as a concern:
Early recognition is key to preventing a complete fracture. Warning signs include:
If you experience persistent thigh or groin pain and you’ve been on bisphosphonates for several years, seek evaluation.
Not everyone on bisphosphonates will develop an atypical thigh bone fracture. Factors that raise risk include:
• Duration of therapy: More than 5 years carries higher risk.
• Glucocorticoid use: Long-term steroids add to bone-weakening effects.
• Rheumatoid arthritis: Chronic inflammation affects bone health.
• Low body weight: Less cushioning around bones.
• Vitamin D deficiency: Impairs bone mineralization.
• Femoral geometry: Certain thigh bone shapes may predispose to stress fractures.
You and your doctor can work together to keep your fracture risk as low as possible:
Periodic risk reassessment
Supplementation
Lifestyle habits
Imaging follow-up
Switching therapies
If you’re on long-term bisphosphonates and notice thigh or groin pain:
You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps and questions for your healthcare provider. https://ubiehealth.com/
Bisphosphonates dramatically lower the chance of common, high-risk fractures (hip, vertebral). Atypical thigh bone fractures remain very uncommon. Key takeaways:
Bisphosphonate-related atypical femoral fractures are rare but real. By understanding warning signs, reassessing long-term therapy and maintaining bone-healthy habits, you can safely benefit from these medications. If you experience unusual thigh or groin pain, seek prompt evaluation. For non-urgent guidance, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always speak to a doctor about anything that could be life-threatening or serious.
(References)
* Bisphosphonates: atypical fractures? Prescrire Int. 2009 Feb;18(99):25. PMID: 19396935.
* Compston JE. Bisphosphonates and atypical femoral fractures: a time for reflection. Maturitas. 2010 Jan;65(1):3-4. doi: 10.1016/j.maturitas.2009.11.002. Epub 2009 Nov 22. PMID: 19932574.
* Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014 Jan;29(1):1-23. doi: 10.1002/jbmr.1998. Epub 2013 Oct 1. PMID: 23712442.
* Tyler W, Bukata S, O'Keefe R. Atypical femur fractures. Clin Geriatr Med. 2014 May;30(2):349-59. doi: 10.1016/j.cger.2014.01.010. Epub 2014 Mar 4. PMID: 24721373.
* Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. PMID: 26350171; PMCID: PMC4906542.
* Yano Y, Kuriyama A, Yano Y, Takeshita A, Hashizume H. Atypical femoral fracture with bisphosphonate use. QJM. 2020 Nov 1;113(11):825-826. doi: 10.1093/qjmed/hcaa073. PMID: 32091607.
* Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525. PMID: 32813950; PMCID: PMC9632334.
* Lo JC, Grimsrud CD. Identifying Complete Atypical Femur Fractures in Adults with Bisphosphonate Exposure. Endocr Pract. 2024 Mar;30(3):278-281. doi: 10.1016/j.eprac.2023.12.012. Epub 2023 Dec 16. PMID: 38110088; PMCID: PMC10950361.
* Anderson PA, Kates SL, Watts NB. Update on Atypical Femoral Fractures. J Bone Joint Surg Am. 2024 Oct 2;106(19):1819-1828. doi: 10.2106/JBJS.23.01439. Epub 2024 Aug 22. PMID: 39172879.
* Alnajmi RAY, Ali DS, Khan AA. Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis. Endocrinol Metab Clin North Am. 2024 Dec;53(4):607-618. doi: 10.1016/j.ecl.2024.08.007. PMID: 39448140.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.